We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
- Authors
Olin, R L; Vogl, D T; Porter, D L; Luger, S M; Schuster, S J; Tsai, D E; Siegel, D L; Cook, R J; Mangan, P A; Cunningham, K; Stadtmauer, E A
- Abstract
Therapeutic options for patients with multiple myeloma whose disease has relapsed after a prior auto-SCT include novel biologic therapies, traditional chemotherapy or a second transplant, with no clear standard of care. Few published studies address the safety and efficacy of a second auto-SCT for relapsed disease. We reviewed the Abramson Cancer Center experience with salvage auto-SCT for relapsed multiple myeloma. Forty-one patients had received a salvage auto-SCT at our institution; the median time between transplants was 37 months (range 3-91). The overall response rate in assessable patients was 55%, and treatment-related mortality was 7%. With a median follow-up time of 15 months, the median PFS was 8.5 months and the median overall survival (OS) was 20.7 months. In a multivariate analysis of OS, independent prognostic factors were >or=5 prior lines of therapy and time to progression after initial auto-SCT of <or=12 months. We conclude that in well-selected patients, salvage auto-SCT is safe and effective for relapsed myeloma.
- Publication
Bone marrow transplantation, 2009, Vol 43, Issue 5, p417
- ISSN
1476-5365
- Publication type
Journal Article
- DOI
10.1038/bmt.2008.334